Market Tracker

01/20 5:16pm ET

Alexion Pharmaceuticals Inc (NASDAQ:ALXN)

131.97
Delayed Data
As of Jan 20
 -2.38 / -1.77%
Today’s Change
109.12
Today|||52-Week Range
162.65
+7.86%
Year-to-Date
The Zacks Analyst Blog Highlights: ExxonMobil, Procter & Gamble, Micron, Macy's and A...
Jan 19 / Zacks.com - Paid Partner Content
Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again
Jan 12 / Zacks.com - Paid Partner Content
Research Reports on Exxon, P&G and the Q4 Earnings Season
Jan 18 / Zacks.com - Paid Partner Content
Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU
Jan 11 / Zacks.com - Paid Partner Content
4 Top Biotech Mutual Funds for 2017
Jan 18 / Zacks.com - Paid Partner Content
Here's Why Alexion Pharmaceuticals, Inc. Stock Gave Up 36% in 2016
Jan 09 / MotleyFool.com - Paid Partner Content
Drugmakers alarmed by Trump pricing threat
Jan 14 / FT.com - Paid Partner Content
Alexion Blood Disorder Drug Gets Orphan Designation in U.S.
Jan 09 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close134.35
Today’s open135.18
Day’s range131.19 - 135.18
Volume1,848,323
Average volume (3 months)2,645,249
Market cap$29.6B
Dividend yield--
Data as of 4:00pm ET, 01/20/2017

Growth & Valuation

Earnings growth (last year)-79.45%
Earnings growth (this year)-6.97%
Earnings growth (next 5 years)+21.40%
Revenue growth (last year)+12.25%
P/E ratio80.0
Price/Sales16.57
Price/Book3.61

Competitors

 Today’s
change
Today’s
% change
ZTSZoetis Inc+0.47+0.88%
BAXBaxter International...-0.34-0.73%
INCYIncyte Corp-0.31-0.26%
REGNRegeneron Pharmaceut...-0.85-0.23%
Data as of 4:01pm ET, 01/20/2017

Financials

Next reporting dateFebruary 16, 2017
EPS forecast (this quarter)$1.25
Annual revenue (last year)$2.5B
Annual profit (last year)$144.4M
Net profit margin5.81%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
David Richard Brennan
Executive Vice President-
Global Operations
Julie O'Neill
Corporate headquarters
New Haven, Connecticut

Forecasts